Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1985 Dec 1;162(6):1837–1851. doi: 10.1084/jem.162.6.1837

Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies

PMCID: PMC2188001  PMID: 3934317

Abstract

Eleven Escherichia coli strains, crossreactive with the capsular polysaccharide (CPS) of Neisseria meningitidis group A (GrA), were detected among 645 stool isolates from healthy families in Cairo, Egypt. 10 of these strains were of the O107:K93:H27 or O107:K93:SP serotypes and may be considered descendents of a single bacterium or as a clone. The remaining crossreactive strain was of the O7:K51:H18 serotype. None of the 11 strains produced enterotoxins and none were enteroinvasive. The purified CPS of these E. coli strains, as well as a polysaccharide (PS) from B. pumilis, strain Sh17, precipitated with equine GrA (H49) antiserum. A partial identity between the E. coli K93, K51 and Sh17 PS on the one hand and the GrA CPS on the other was observed by double immunodiffusion when reacted against the H49 antiserum. Four K93 strains and one K51 strain were found among 320 E. coli strains from patients at the Clinical Center, National Institutes of Health, and three K93 strains were found in 105 stool samples from children in Copenhagen. The data from these three surveys suggest that these crossreactive E. coli are common organisms and could serve as a stimulus for "natural" GrA CPS antibodies. Quantitative precipitation analysis showed that K51, K93, and Sh17 PS precipitated 25, 46.8, and 50% of H49 antibodies, respectively. Absorption of H49 antiserum with the GrA CPS removed its precipitating activity with the E. coli K93, K51, and Sh17 PS. Absorption of H49 antiserum with either K51 CPS or Sh17 PS removed the homologous crossreactivity only, whereas K93 CPS absorbed both K93 and K51 reactivities. Antibodies, raised by intravenous injection of formalinized E. coli K93 or K51 cells into rabbits, precipitated with GrA CPS and were bactericidal against GrA meningococci. The crossreaction between the E. coli K93 and the GrA CPS was unexpected since these two CPS are compositionally so dissimilar.

Full Text

The Full Text of this article is available as a PDF (2.2 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AYCOCK W. L., MUELLER J. H. Meningococcus carrier rates and meningitis incidence. Bacteriol Rev. 1950 Jun;14(2):115–160. doi: 10.1128/br.14.2.115-160.1950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev Infect Dis. 1981 Mar-Apr;3 (Suppl):S1–17. doi: 10.1093/clinids/3.supplement_1.s1. [DOI] [PubMed] [Google Scholar]
  3. Bundle D. R., Smith I. C., Jennings H. J. Determination of the structure and conformation of bacterial polysaccharides by carbon 13 nuclear magnetic resonance. Studies on the group-specific antigens of Neisseria meningitidis serogroups A and X. J Biol Chem. 1974 Apr 10;249(7):2275–2281. [PubMed] [Google Scholar]
  4. Bøvre K., Gedde-Dahl T. W. Epidemiological patterns of meningococcal disease in Norway 1975-1979. NIPH Ann. 1980 Dec;3(2):9–22. [PubMed] [Google Scholar]
  5. Counts G. W., Gregory D. F., Spearman J. G., Lee B. A., Filice G. A., Holmes K. K., Griffiss J. M. Group A meningococcal disease in the U.S. Pacific Northwest: epidemiology, clinical features, and effect of a vaccination control program. Rev Infect Dis. 1984 Sep-Oct;6(5):640–648. doi: 10.1093/clinids/6.5.640. [DOI] [PubMed] [Google Scholar]
  6. Counts G. W., Petersdorf R. G. 'The wheel within a wheel': meningococcal trends. JAMA. 1980 Nov 14;244(19):2200–2201. [PubMed] [Google Scholar]
  7. Cross A. S., Gemski P., Sadoff J. C., Orskov F., Orskov I. The importance of the K1 capsule in invasive infections caused by Escherichia coli. J Infect Dis. 1984 Feb;149(2):184–193. doi: 10.1093/infdis/149.2.184. [DOI] [PubMed] [Google Scholar]
  8. Dean A. G., Ching Y. C., Williams R. G., Harden L. B. Test for Escherichia coli enterotoxin using infant mice: application in a study of diarrhea in children in Honolulu. J Infect Dis. 1972 Apr;125(4):407–411. doi: 10.1093/infdis/125.4.407. [DOI] [PubMed] [Google Scholar]
  9. EICKHOFF T. C., FINLAND M. CHANGING SUSCEPTIBILITY OF MENINGOCOCCI TO ANTIMICROBIAL AGENTS. N Engl J Med. 1965 Feb 25;272:395–398. doi: 10.1056/NEJM196502252720804. [DOI] [PubMed] [Google Scholar]
  10. Epidemiological surveillance and control of cerebrospinal meningitis in Africa. WHO Chron. 1973 Sep;27(9):347–351. [PubMed] [Google Scholar]
  11. Evans J. R., Artenstein M. S., Hunter D. H. Prevalence of meningococcal serogroups and description of three new groups. Am J Epidemiol. 1968 May;87(3):643–646. doi: 10.1093/oxfordjournals.aje.a120854. [DOI] [PubMed] [Google Scholar]
  12. Filice G. A., Englender S. J., Jacobson J. A., Jourden J. L., Burns D. A., Gregory D., Counts G. W., Griffiss J. M., Fraser D. W. Group A meningococcal disease in skid rows: epidemiology and implications for control. Am J Public Health. 1984 Mar;74(3):253–254. doi: 10.2105/ajph.74.3.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Frasch C. E., Robbins J. D. Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model. J Exp Med. 1978 Mar 1;147(3):629–644. doi: 10.1084/jem.147.3.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Goldschneider I., Gotschlich E. C., Artenstein M. S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969 Jun 1;129(6):1307–1326. doi: 10.1084/jem.129.6.1307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Goldschneider I., Gotschlich E. C., Artenstein M. S. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969 Jun 1;129(6):1327–1348. doi: 10.1084/jem.129.6.1327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Goldschneider I., Lepow M. L., Gotschlich E. C., Mauck F. T., Bachl F., Randolph M. Immunogenicity of group A and group C meningococcal polysaccharides in human infants. J Infect Dis. 1973 Dec;128(6):769–776. doi: 10.1093/infdis/128.6.769. [DOI] [PubMed] [Google Scholar]
  17. Gotschlich E. C., Rey M., Etienne J., Sanborn W. R., Triau R., Cvjetanović B. The immunological responses observed in field studies in Africa with group A meningococcal vaccines. Prog Immunobiol Stand. 1971;5:485–491. [PubMed] [Google Scholar]
  18. Gotschlich E. C., Rey M., Triau R., Sparks K. J. Quantitative determination of the human immune response to immunization with meningococcal vaccines. J Clin Invest. 1972 Jan;51(1):89–96. doi: 10.1172/JCI106801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Grados O., Ewing W. H. Antigenic relationship between Escherichia coli and Neisseria meningitidis. J Infect Dis. 1970 Jul-Aug;122(1):100–103. doi: 10.1093/infdis/122.1-2.100. [DOI] [PubMed] [Google Scholar]
  20. Griffiss J. M. Epidemic meningococcal disease: synthesis of a hypothetical immunoepidemiologic model. Rev Infect Dis. 1982 Jan-Feb;4(1):159–172. doi: 10.1093/clinids/4.1.159. [DOI] [PubMed] [Google Scholar]
  21. Guerrant R. L., Brunton L. L., Schnaitman T. C., Rebhun L. I., Gilman A. G. Cyclic adenosine monophosphate and alteration of Chinese hamster ovary cell morphology: a rapid, sensitive in vitro assay for the enterotoxins of Vibrio cholerae and Escherichia coli. Infect Immun. 1974 Aug;10(2):320–327. doi: 10.1128/iai.10.2.320-327.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Guirguis N., Hafez K., El Kholy M. A., Robbins J. B., Gotschlich E. C. Bacterial meningitis in Egypt: analysis of CSF isolates from hospital patients in Cairo, 1977-78. Bull World Health Organ. 1983;61(3):517–524. [PMC free article] [PubMed] [Google Scholar]
  23. Hochstein H. D., Elfin R. J., Cooper J. F., Seligmann E. B., Jr, Wolff S. M. Further developments of Limulus Amebocyte Lysate test. Bull Parenter Drug Assoc. 1973 May-Jun;27(3):139–148. [PubMed] [Google Scholar]
  24. Insel R. A., Anderson P. W., Jr Cross-reactivity with Escherichia coli K100 in the human serum anticapsular antibody response to Haemophilus influenzae type B. J Immunol. 1982 Mar;128(3):1267–1270. [PubMed] [Google Scholar]
  25. Kasper D. L., Winkelhake J. L., Zollinger W. D., Brandt B. L., Artenstein M. S. Immunochemical similarity between polysaccharide antigens of Escherichia coli 07: K1(L):NM and group B Neisseria meningitidis. J Immunol. 1973 Jan;110(1):262–268. [PubMed] [Google Scholar]
  26. LOVE B. D., Jr, FINLAND M. In vitro susceptibility of meningococci to eleven antibiotics and sulfadiazine. Am J Med Sci. 1954 Nov;228(5):534–539. doi: 10.1097/00000441-195411000-00006. [DOI] [PubMed] [Google Scholar]
  27. Laurell C. B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966 Apr;15(1):45–52. doi: 10.1016/0003-2697(66)90246-6. [DOI] [PubMed] [Google Scholar]
  28. Myerowitz R. L., Gordon R. E., Robbins J. B. Polysaccharides of the genus Bacillus cross-reactive with the capsular polysaccharides of Diplococcus pneumoniae type 3, Haemophilus influenzae type b, and Neisseria meningitidis group A. Infect Immun. 1973 Dec;8(6):896–900. doi: 10.1128/iai.8.6.896-900.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Nicholson A., Lepow I. H. Host defense against Neisseria meningitidis requires a complement-dependent bactericidal activity. Science. 1979 Jul 20;205(4403):298–299. doi: 10.1126/science.451601. [DOI] [PubMed] [Google Scholar]
  30. Orskov F., Orskov I. Escherichia coli O:H serotypes isolated from human blood. Prevalence of the K1 antigen with technical details of O and H antigenic determination. Acta Pathol Microbiol Scand Suppl. 1975 Dec;83(6):595–600. [PubMed] [Google Scholar]
  31. Orskov F., Orskov I., Jann B., Jann K. Immunoelectrophoretic patterns of extracts from all Escherichia coli O and K antigen test strains: correlation with pathogenicity. Acta Pathol Microbiol Scand B Microbiol Immunol. 1971;79(2):142–152. doi: 10.1111/j.1699-0463.1971.tb02141.x. [DOI] [PubMed] [Google Scholar]
  32. Orskov I., Orskov F., Jann B., Jann K. Serology, chemistry, and genetics of O and K antigens of Escherichia coli. Bacteriol Rev. 1977 Sep;41(3):667–710. doi: 10.1128/br.41.3.667-710.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Peltola H. Group A meningococcal polysaccharide vaccine and course of the group A meningococcal epidemic in Finland. Scand J Infect Dis. 1978;10(1):41–44. doi: 10.3109/inf.1978.10.issue-1.09. [DOI] [PubMed] [Google Scholar]
  34. Peltola H. Meningococcal disease: still with us. Rev Infect Dis. 1983 Jan-Feb;5(1):71–91. doi: 10.1093/clinids/5.1.71. [DOI] [PubMed] [Google Scholar]
  35. Rao A. S., Liao J., Kabat E. A., Osserman E. F., Harboe M., Nimmich W. Immunochemical studies on human monoclonal macroglobulins with specificities for 3,4-pyruvylated D-galactose and 4,6-pyruvylated D-glucose. J Biol Chem. 1984 Jan 25;259(2):1018–1026. [PubMed] [Google Scholar]
  36. Robbins J. B., Myerowitz L., Whisnant J. K., Argaman M., Schneerson R., Handzel Z. T., Gotschlich E. C. Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3. Infect Immun. 1972 Nov;6(5):651–656. doi: 10.1128/iai.6.5.651-656.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Robbins J. B. Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future. Immunochemistry. 1978 Nov;15(10-11):839–854. doi: 10.1016/0161-5890(78)90117-7. [DOI] [PubMed] [Google Scholar]
  38. SERENY B. Experimental shigella keratoconjunctivitis; a preliminary report. Acta Microbiol Acad Sci Hung. 1955;2(3):293–296. [PubMed] [Google Scholar]
  39. Schneerson R., Bradshaw M., Whisnant J. K., Myerowitz R. L., Parke J. C., Jr, Robbins J. B. An Escherichia coli antigen cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b: occurrence among known serotypes, and immunochemical and biologic properties of E. coli antisera toward H. influenzae type b. J Immunol. 1972 Jun;108(6):1551–1562. [PubMed] [Google Scholar]
  40. Schneerson R., Robbins J. B. Induction of serum Haemophilus influenzae type B capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075:K100:H5. N Engl J Med. 1975 May 22;292(21):1093–1096. doi: 10.1056/NEJM197505222922103. [DOI] [PubMed] [Google Scholar]
  41. Vann W. F., Liu T. Y., Robbins J. B. Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide. Infect Immun. 1976 Jun;13(6):1654–1662. doi: 10.1128/iai.13.6.1654-1662.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Weeke B. Rocket immunoelectrophoresis. Scand J Immunol Suppl. 1973;1:37–46. doi: 10.1111/j.1365-3083.1973.tb03777.x. [DOI] [PubMed] [Google Scholar]
  43. Wiggins G. L., Hollis D. G., Weaver R. Prevalence of serogroups and sulfonamide resistance of meningococci from the civilian population in the United States, 1964-1970. Am J Public Health. 1973 Jan;63(1):59–65. doi: 10.2105/ajph.63.1.59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Wong K. H., Barrera O., Sutton A., May J., Hochstein D. H., Robbins J. D., Robbins J. B., Parkman P. D., Seligmann E. B., Jr Standardization and control of meningococcal vaccines, group A and group C polysaccharides. J Biol Stand. 1977;5(3):197–215. doi: 10.1016/s0092-1157(77)80005-x. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES